Kalaris Therapeutics Inc (KLRS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Operating Expenses | 46,152 | 51,732 | 199,901 | 171,202 | 169,818 |
| Operating Income | -46,152 | -51,732 | -199,901 | -171,202 | -169,818 |
| Interest Expense | 1,443 | 2,701 | 0 | 0 | 0 |
| Other Income | 4,157 | -14,734 | 9,357 | 2,227 | -1,137 |
| Pre-tax Income | -43,438 | -69,167 | -190,544 | -168,975 | -170,955 |
| Income Tax | N/A | N/A | -126 | -265 | 1,007 |
| Net Income Continuous | -43,438 | -69,167 | -190,418 | -168,710 | -171,962 |
| Net Income | $-43,438 | $-69,167 | $-190,418 | $-168,710 | $-171,962 |
| EPS Basic Total Ops | -2.85 | -51.77 | -42.09 | -50.57 | -62.99 |
| EPS Basic Continuous Ops | -2.85 | -51.77 | -42.09 | -50.60 | -62.97 |
| EPS Diluted Total Ops | -2.85 | -51.77 | -42.09 | -50.57 | -62.99 |
| EPS Diluted Continuous Ops | -2.85 | -51.77 | -42.09 | -50.60 | -62.97 |
| EPS Diluted Before Non-Recurring Items | -2.85 | -9.70 | -42.07 | -50.58 | -62.99 |
| EBITDA(a) | $-46,538 | $-51,732 | $-199,503 | $-170,479 | $-169,629 |